Who
Peter Kaiser
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, Ocular Therapeutix.
In numbers
- Trades disclosed
- 19
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $478K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Oct 2024
- Last trade
- 2 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Oct 2026filed 6 Oct 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $70K9,990 at $7.05 | filing |
| 24 Aug 2026filed 26 Aug 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $33K3,035 at $10.77 | filing |
| 24 Aug 2026filed 26 Aug 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $33K3,035 at $10.77 | filing |
| 26 May 2026filed 28 May 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $24K2,967 at $8.20 | filing |
| 26 May 2026filed 28 May 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $24K2,967 at $8.20 | filing |
| 23 Feb 2026filed 25 Feb 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $23K2,810 at $8.28 | filing |
| 23 Feb 2026filed 25 Feb 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $23K2,810 at $8.28 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —79,112 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —240,932 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —240,932 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —79,112 at $0.00 | filing |
| 24 Nov 2025filed 26 Nov 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $36K3,007 at $12.02 | filing |
| 2 Oct 2025filed 6 Oct 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $106K9,653 at $11.03 | filing |
| 25 Aug 2025filed 27 Aug 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $36K3,011 at $12.04 | filing |
| 23 May 2025filed 27 May 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $21K2,974 at $7.17 | filing |
| 24 Feb 2025filed 26 Feb 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $21K3,009 at $6.87 | filing |
| 25 Nov 2024filed 27 Nov 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $26K2,897 at $9.01 | filing |
| 2 Oct 2024filed 4 Oct 2024 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 2 Oct 2024filed 4 Oct 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Todd Anderman Sells 11,984 SharesOCUL · themarketsdaily.com · 15 Oct 2026Ocular Therapeutix (NASDAQ:OCUL) Upgraded to Strong-Buy at UBS GroupOCUL · dailypolitical.com · 14 Oct 2026Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)OCUL · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Peter Kaiser; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.